Asmacure Ltée

company

About

Asmacure Ltée develops proprietary compounds that target cholinergic receptors for the treatment of pulmonary airway diseases.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$9M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2002
Number Of Employee
1 - 10
Operating Status
Active

Asmacure Ltée is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases.

The company’s lead compound, ASM-024, has a novel multi-functional mechanism of action with nicotinic and muscarinic effects. ASM-024 has demonstrated the capabilities of anti-inflammation, bronchoprotection, and smooth muscle relaxation in pre-clinical asthma models.

Administered as a solution for nebulization in asthma patients, ASM-024 demonstrated clinical proof of concept in a phase 2 trial with significant effects on FEV1 and methacholine PC20. Asmacure has advanced ASM-024 into the clinic for the treatment of moderate asthma and COPD with a dry powder for inhalation (DPI) formulation. The DPI is a preferred dosage form for many patients and should allow ASM-024 to be delivered with greater lung deposition yielding the potential for a lower and more optimal dose.

Asmacure was founded by Dr. Yvon Cormier, a noted pulmonologist, and Dr Evelyne Israel-Assayag in 2002 and is based in Quebec City, Quebec, Canada.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$9M
Asmacure Ltée has raised a total of $9M in funding over 2 rounds. Their latest funding was raised on May 10, 2007 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 10, 2007 Series A $9M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Asmacure Ltée is funded by 1 investors. Innovatech Québec are the most recent investors.
Investor Name Lead Investor Funding Round
Innovatech Québec Series A